Medical record review was conducted on 14 patients with neuropathologically confirmed Alzheimer's disease, all of whom had been treated with antipsychotic medications, to determine the relationship between neuropathology and the development of tardive dyskinesia. Four cases were found to have chart descriptions of hyperkinetic movement disorders consistent with tardive dyskinesia. When the group with tardive dyskinesia was compared to the group without tardive dyskinesia, there were no statistically significant differences regarding gender, age of onset of dementia, duration of de mentia, age at death, or duration of antipsychotic treatment. Neuropathologic comparisons revealed greater degenerative changes in the substantia nigra in those patients with tardive dyskinesia. These preliminary observations suggest that patients with Alzheimer's disease and significant coexisting substantia nigra pathologic changes may be at higher risk for developing tardive dyskinesia when treated with antipsychotic medication (J Geriatr Psychiatry Neurol 1991;4:79-85).
Get full access to this article
View all access options for this article.
References
1.
Michel K., Kolakowska T.: A survey of prescribing psychotropic drugs in two psychiatric hospitals. Br J Psychiatry1981;138:217-221.
2.
Prien RF, Haber PA, Caffey EM: Use of psychoactive drugs in patients with psychiatric disorders: Survey conducted in twelve Veterans Administration Hospitals. J Am Geriatr Soc1975;23:104-112.
3.
Hansen TE, Casey DE, Vollmer WM: Is there an epidemic of tardive dyskinesia? in Casey DE, Gardos G (eds): Tardive dyskinesia and neuroleptics: From dogma to reason. Washington, DC, American Psychiatric Press, 1988.
4.
Baldessarini RF: Clinical and epidemiologic aspects of tardive dyskinesia. J Clin Psychiatry1985;46:8-13.
5.
Kane JM, Woerner M., Lieberman J.: Tardive dyskinesia: Prevalence, incidence, and risk factors. J Clin Psychopharmacol1988;8:52S-56S.
6.
Lieberman J. , Kane JM, Woerner M., et al: Prevalence of tardive dyskinesia in elderly samples. Psychopharmacol Bull1984 ;20:382-386.
7.
Lohr JB, Wisniewski AA: Movement disorders: A neuropsychiatric approach. New York , Guilford Press, 1987.
8.
Satlin A., Davar G., Cole JO, et al: Dyskinesia in the demented elderly (NR135), abstract. Presented at the American Psychiatric Association Annual Meeting , San Francisco, 1989.
9.
Jeste DV, Wyatt RJ: Changing epidemiology of tardive dyskinesia: An overview. Am J Psychiatry1981;138:279-309.
10.
Jeste DV, Wyatt RJ: Understanding and Treating Tardive Dyskinesia. New York , Guilford Press, 1982.
11.
TaskForce on Late Neurologic Effects of Antipsychotic Drugs: Tardive dyskinesia: Summary of a task force report of the American Psychiatric Association. Am J Psychiatry1980;137:1163-1172.
12.
Kane JM, Smith JM: Tardive dyskinesia: Prevalence and risk factors, 1959-1979. Arch Gen Psychiatry1982;39:473-481.
13.
Toenniessen LM, Casey DE, McFarland BH: Tardive dyskinesia in the aged. Arch Gen Psychiatry1985;42:278-287.
14.
Klawans HL, Tanner CM, Goetz CG: Epidemiology and pathophysiology of tardive dyskinesia, in Jankovic J, Tolosa E (eds): Advances in Neurology, Vol 49: Facial Dyskinesias. New York, Raven Press, 1988, pp 185-197.
15.
McKhann G., Drachman D., Folstein M., et al: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology1984 ;34:939-944.
16.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd ed, revised. Washington, DC, American Psychiatric Association, 1987.
17.
Khachaturian ZS: Diagnosis of Alzheimer's disease. Arch Neurol1985;42:1097-1105.
18.
Schooler N. , Kane JM: Research diagnosis for tardive dyskinesia (RD-TD). Arch Gen Psychiatry1982;39:486-487.
19.
Ditter SM, Mirra SS: Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology1987;37:754-760.
20.
Jellinger K. : Overview of morphological changes in Parkinson's disease. Adv Neurol1987;45:1-18.
21.
Klawans HL, Goetz CG, Perlik S.: Tardive dyskinesia: Review and update. Am J Psychiatry1980;137:900-908.
22.
Smith JM, Oswald WT, Kuchanski LT, et al: Tardive dyskinesia: Age and sex differences in hospitalized schizophrenics. Psychopharmacology1978;58:207-211.
23.
Klawans HL, Tanner CM: Movement disorders in the elderly, in Albert ML (ed): Clinical Neurology of Aging. New York, Oxford University Press, 1984, pp 387-403.
24.
Koller WC: Idiopathic oral-facial dyskinesia, in Jankovic J, Tolosa E (eds): Advances in Neurology, Vol. 49: Facial Dyskinesias. New York, Raven Press, 1988, pp 177-183.
25.
Davis JR, Cummings JL: Clinical variants of tardive dyskinesia. Neuropsychiatry Neuropsychol Behav Neurol1988;1:31-38.
26.
Gardos G., Cole JO, Salomon M., Schniebolk S.: Clinical forms of severe tardive dyskinesia. Am J Psychiatry1987;144:895- 902.
27.
Kidger T., Barnes Tre, Trauer T., Taylor PJ: Sub-syndromes of tardive dyskinesia. Psychol Med1980;10:513-520.
28.
Hunter R., Blackwood W., Smith MC, Cumings JN: Neuropathologic findings in three cases of persistent dyskinesia following phenothiazine medication. J Neurol Sci1968 ;7:263-273.
29.
Kaufman MA: Alternative diagnoses to tardive dyskinesia: Neuropathologic findings in three suspected cases, in Roizin L, Shiraki H, Grcevic N (eds): Neurotoxicology. New York, Raven Press, 1977, pp 57-61.
30.
Arai N., Amano N., Iseki E., et al: Tardive dyskinesia with inflated neurons of the cerebellar dentate nucleus. Acta Neuropathol (Berl) 1987;73:38-42.
31.
Campbell WG , Raskind MA, Gordon T., Shaw CM: Iron pigment in the brain of a man with tardive dyskinesia. Am J Psychiatry1985;142:364-365.
32.
Christensen E., Moller JE, Faurbye A.: Neuropathological investigation of 28 brains from patients with dyskinesia. Acta Psychiatr Scand1970;46:14-23.
33.
Gross H., Kaltenback E.: Neuropathologic findings in persistent hyperkinesia after neuroleptic long-term therapy, in Cerletti A, Bove FJ (eds): The Present Status of Psychotropic Drugs. Amsterdam, Excerpta Medica , 1969, pp 474-476.
34.
Jellinger K.: Neuropathologic findings after neuroleptic long-term therapy, in Roizin L, Shiraki H, Grcevic N (eds): Neurotoxicology. New York, Raven Press, 1977, pp 25-42.
35.
Leverenz J. , Sumi M.: Parkinson's disease in patients with Alzheimer's disease. Arch Neurol1986;43:662-664.
36.
Joachim CL, Morris JH, Selkoe DJ: Clinically diagnosed Alzheimer's disease: Autopsy results in 150 cases. Ann Neurol1988;24:50-56.
37.
Bergeron C. , Pollanen M.: Lewy bodies in Alzheimer's disease—one or two diseases?Alzheimer Dis Assoc Disord1989;3:197-204.
38.
Gibb Wrg, Lees AJ: Prevalence of Lewy bodies in Alzheimer's disease. Ann Neurol1989;26:691-692.
39.
Gibb Wrg, Montjoy CQ, Mann Dma, Lees AJ: A pathological study of the association between Lewy body disease and Alzheimer's disease. J Neurol Neurosurg Psychiatry1989 ;52:701-708.
40.
Morris JC, Drazner M., Fulling K., et al: Clinical and pathological aspects of parkinsonism in Alzheimer's disease. Arch Neurol1989;46:651-657.
41.
Marsden CD, Tarsy D., Baldessarini RJ: Spontaneous and drug-induced movement disorders in psychotic patients, in Benson DF, Blumer D (eds): Psychiatric Aspects of Neurologic Disease . New York, Grune & Stratton , 1975, pp 214-265.
42.
Bell Rch, Smith RC: Tardive dyskinesia: Characterization and prevalence in a state wide system . J Clin Psychol1978;39:39-47.
43.
Gibson AC: Depot fluphenazine and tardive dyskinesia in an outpatient population, in Faun WE, Smith RC, Davis JM, Domino EF (eds): Tardive Dyskinesia: Research and Treatment . New York, SP Medical and Scientific , 1980, pp 315-324.
44.
Guy W.: ECDEN Assessment Manual for Psychopharmacology. Washington, DC, US Department of Health Education and Welfare, 1976, pp 534-537.
